Table 1.
Descriptive characteristics of the sample, and bivariate associations. Used Pearson’s Chi-square test, and t-test for continuous variables. Pearson’s Chi-square test (χ2) for categorical variables
| Variables N (%) | Total population | AEFI (yes) | AEFI (no) | p-value* |
|---|---|---|---|---|
|
Sex Women Men |
152,690 (48.5) 161,974 (51.5) |
946 (0.6) 463 (0.3) |
151,744 (99.4) 161,511 (99.7) |
<0.001 |
| Age (mean ± SE) | 47.5 ± 0.03 | 41.9 ± 0.46 | 47.5 ± 0.03 | <0.001 |
|
Age 0-19 20-39 40-59 ≥ 60 |
17,456 (5.5) 85,197 (27.1) 130,351 (41.4) 81,660 (26.0) |
134 (0.8) 546 (0.6) 467 (0.4) 262 (0.3) |
17,332 (99.2) 84,651 (99.4) 129,884 (99.6) 81,398 (99.7) |
<0.001 |
|
Category of vulnerability Age ≥ 60 Previous pathology Healthcare workers Residents in confined communities Professional risk Military Pregnant women None (general population) Others |
81,660 (26.0) 27,252 (8.7) 1,087 (0.4) 429 (0.1) 361 (0.1) 152 (0.1) 40 (0.0) 199,472 (63.4) 4,211 (1.34) |
262 (0.3) 172 (0.6) 3 (0.3) 3 (0.7) 4 (1.1) 3 (2.0) 0 (0.0) 945 (0.5) 17 (0.4) |
81,398 (99.7) 27,080 (99.4) 1,084 (99.7) 426 (99.3) 357 (98.9) 149 (98.0) 40 (100) 198,527 (99.5) 4,194 (99.6) |
<0.001 |
|
Type of vaccine Pfizer (Comirnaty) Astrazeneca (Vaxzevria) Moderna (Spikevax) Janssen (Johnson & Johnson) |
270,380 (85.9) 21,636 (6.9) 14,544 (4.6) 8,104 (2.6) |
1,199 (0.4) 72 (0.3) 85 (0.6) 53 (0.7) |
269,181 (99.6) 21,564 (99.7) 14,459 (99.4) 8,051 (99.3) |
<0.001 |
|
Dosage First dose Second dose |
255,173 (81.1) 59,491 (18.9) |
1,273 (0.5) 136 (0.2) |
253,900 (99.5) 59.355 (99.8) |
<0.001 |
| Latency of AEFI in minutes (mean ± SD) | n.a. | 17.0 ± 0.43 | n.a. | n.a. |
|
Type of AEFI Vagal response Anxiety reaction Dizziness Paresthesias Allergic reaction Hypertensive crisis Other |
n.a. | 423 (30.0) 339 (24.1) 296 (21.0) 99 (7.0) 93 (6.6) 78 (5.5) 81 (5.8) |
n.a. | n.a. |
* p-value estimated comparing subjects who developed immediate AEFI compared to those without
SE: standard error; n.a.: not applicable